The Carcinoid Syndrome
- 11 September 1986
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 315 (11) , 702-704
- https://doi.org/10.1056/nejm198609113151109
Abstract
The carcinoid syndrome is an endocrine manifestation of neoplastic enterochromaffin cells. The humoral consequences of enterochromaffin carcinoid tumors include cutaneous flushing, diarrhea, valvular lesions of the right side of the heart, bronchoconstriction, and facial telangiectasia. Because these malignant tumors grow at a relatively slow rate, the morbidity during much of the illness they cause derives from their endocrine effects, including cardiac valvular lesions, which contribute substantially to mortality. Therefore, at a time when chemotherapy of these cancers is frequently unsuccessful, therapeutic measures that address their endocrine manifestations are realistic.The typical carcinoid tumors that arise from the gastrointestinal tract cause . . .Keywords
This publication has 15 references indexed in Scilit:
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- Measurement and partial characterization of the multiple forms of neurokinin A-like immunoreactivity in carcinoid tumoursRegulatory Peptides, 1986
- Neuropeptide K: A major tachykinin in plasma and tumor tissues from carcinoid patientsBiochemical and Biophysical Research Communications, 1985
- Elevated concentrations of substance p and 5-HT in plasma in patients with carcinoid tumorsCancer, 1984
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- A potent cyclic hexapeptide analogue of somatostatinNature, 1981
- Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.Gut, 1981
- Blockade of the Flush Associated with Metastatic Gastric Carcinoid by Combined Histamine H1and H2Receptor AntagonistsNew England Journal of Medicine, 1979
- The Carcinoid FlushNew England Journal of Medicine, 1978
- EFFICACY OF SOMATOSTATIN IN A PATIENT WITH CARCINOID SYNDROMEThe Lancet, 1978